Clinical trials: Nut Hypersensitivities
Peanut Hypersensitivity
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.
- Trial name
- PAIE/Xolair (NCT00932282)
- Testing
- Peanut Oral Immunotherapy, Omalizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Peanut Allergy
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: Identify the basic immune mechanisms which can explain the differences in…
- Trial name
- POISED (NCT02103270)
- Testing
- Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Food Allergy Peanut, Food Allergy in Infants
Intervention to Reduce Early (Peanut) Allergy in Children
iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines.
- Trial name
- iREACH (NCT04604431)
- Testing
- iREACH CDS Tool
- Where
- 30 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Peanut Hypersensitivity
Oral Immunotherapy (OIT) for Peanut Allergy
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions…
- Trial name
- PnOIT3 (NCT00815035)
- Testing
- Peanut OIT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Hypersensitivity, Food Hypersensitivity
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in…
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
- Trial name
- NCT01084174
- Testing
- Peanut powder, Peanut extract
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
Food Allergy, Food Allergy Peanut
Preventing Anaphylaxis With Acalabrutinib
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis.
- Trial name
- NCT05038904
- Testing
- Acalabrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Peanut Allergy
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
- Trial name
- EPITOPE (NCT03211247)
- Testing
- Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part B Viaskin Peanut 250 mcg
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- DBV Technologies
Peanut Hypersensitivity, Food Hypersensitivity
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after…
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
- Trial name
- SLIT-TLC (NCT01373242)
- Testing
- Liquid peanut extract (Peanut SLIT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
- Trial name
- NCT03337542
- Testing
- AR101
- Where
- 60 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Safety Study of Viaskin Peanut to Treat Peanut Allergy
This study evaluates the safety of Viaskin Peanut 250 µg in the treatment of peanut allergy in children from 4 to 11 years of age.
- Trial name
- REALISE (NCT02916446)
- Testing
- Viaskin Peanut 250 µg
- Where
- 32 sites in United States, Canada
- Volunteers
- 393 people
- Sponsor
- DBV Technologies
Food Hypersensitivity
Oral Immunotherapy for Peanut Allergy (PMIT)
The purpose of this study is to determine if mucosal peanut immunotherapy will make subjects who have peanut allergy less allergic and induce changes in their immune system.
- Trial name
- PMIT (NCT00597675)
- Testing
- Peanut OIT
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Salvage Peanut Oral Immunotherapy Study
The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy…
- Trial name
- SOIT (NCT03251508)
- Testing
- Peanut OIT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Food Hypersensitivity
Mechanisms of Desensitization During Peanut Oral Immunotherapy
The purpose of this study is to attempt to understand how desensitization works in peanut allergic children who are undergoing oral immunotherapy (OIT) to peanut.
- Trial name
- PnOIT4 (NCT01814241)
- Testing
- Open label peanut OIT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy.
- Trial name
- NCT05138757
- Testing
- Prebiotic
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Allergy, Peanut
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts.
- Trial name
- NCT05432388
- Testing
- LOU064
- Where
- 24 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
Long-term Extension Study of Ligelizumab in Food Allergy
This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
- Trial name
- NCT05678959
- Testing
- Ligelizumab 120 mg, Ligelizumab 240 mg
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy
The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
- Trial name
- WOIT (NCT01546753)
- Testing
- Walnut Protein Powder, Open-label Walnut Protein Powder
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Food Allergy
The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
In Finland, the estimated prevalence of physician-diagnosed food allergy in 1-4 year old children is 9%, and the most common allergen is milk. The overall food allergy has been reported to be 3.7%.
- Trial name
- NCT01822353
- Testing
- Dietary supplement
- Where
- Finland
- Volunteers
- 23 people
- Sponsor
- Helsinki University Central Hospital